EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Concomitant use of glucagon-like peptide-1 receptor agonists in patients with psoriasis or hidradenitis suppurativa receiving bimekizumab: Cross-sectional analysis of US claims data

Martina Porter, Ana Macedo, Janek Rudnik, Aijing Shang, Evelina Van Ree, Chao Song, Jeremy Schafer, Pablo De la Cueva

SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · s862

DOI: 10.25251/5xcv9n94 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Patients with psoriasis (PSO) and hidradenitis suppurativa (HS) have higher rates of comorbid obesity and type 2 diabetes mellitus (T2DM) than the general population. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are indicated for obesity/T2DM. Bimekizumab (BKZ), a humanized IgG1 monoclonal antibody selectively inhibiting IL-17F in addition to IL-17A, is approved for moderate-to-severe plaque PSO and HS. Evaluating the extent of concomitant GLP-1RA/BKZ use in routine practice, and characterizing patients receiving both treatments, can inform management of PSO/HS and comorbid obesity/T2DM. We assessed the prevalence of concomitant GLP-1RA use in BKZ-treated patients with PSO/HS and the characteristics of those receiving both treatments in a cross-sectional analysis of US claims data. Procedure: Data were taken from the Komodo Health database, including open/closed claims from Medicare and Commercial insurances (BKZ US approval: Oct 2023 for PSO; Nov 2024 for HS). Eligible patients: ≥18 years, with a PSO/HS diagnosis, and ≥1 BKZ claim in the selection period (Nov 1, 2023–Dec 7, 2025). Concomitant GLP-1RA/BKZ use was defined as any treatment overlap in this period; index date was first overlap day. For overlap before Nov 1, 2023, index date was Nov 1, 2023; in patients with multiple episodes of concomitant GLP-1RA/BKZ use, first overlap was index date. Primary endpoint was prevalence of concomitant GLP-1RA/BKZ use for the whole selection period and by year, evaluated per indication. Data are reported as observed with 95% CI. Subgroup analyses were performed by sex, age group, and comorbidity; sensitivity analysis was restricted to closed claims. Secondary endpoint was patient characteristics at index date for those receiving concomitant GLP-1RA/BKZ treatment. Results: During selection period, 18,665 and 5,082 patients with PSO and HS received BKZ treatment, respectively. Prevalence (95% CI) of concomitant GLP-1RA use was 20.1% (19.5–20.7%) and 23.0% (21.9–24.2%). GLP-1RA use was higher in females and those ≥46–≤65 years. Patients with obesity and T2DM had higher prevalence of GLP-1RA use vs patients with neither (PSO/HS: 48.1%/49.5% vs 4.2%/4.3%); sensitivity analysis provided similar results. Among PSO/HS patients receiving both GLP-1RA and BKZ (N=3,754/N=1,170), mean age: 53.6/46.5 years; females: 62.2%/74.3%. For both PSO/HS groups, most patients (76.7%/82.5%) started GLP-1RA before BKZ, 89.6%/84.6% were biologic-experienced; >95% had a cardiometabolic condition. Semaglutide and tirzepatide accounted for ~40% and ~50% of prescribed GLP-1RAs in all BKZ-treated patients, respectively. Dermatologists often prescribed BKZ (PSO: 39.8%; HS: 50.9%) but rarely GLP-1RAs (PSO: 0.4%; HS: 1.3%). Conclusion: In routine clinical practice during study period, concomitant GLP-1RA use (>20% overall) in bimekizumab-treated patients with PSO/HS increased. This, along with the high comorbidity rates in patients receiving concomitant treatment, reflects a complex and multimorbid population. Most PSO/HS patients initiated bimekizumab after GLP-1RAs, suggesting continued need for effective treatment of these inflammatory diseases alongside management of metabolic comorbidities.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →